HOTH - Hoth Therapeutics confirms HT-003 potential to inhibit acne pathogenic gene expression

Hoth Therapeutics (HOTH) completes the first phase of the research in examining the ability of HT-003 in blocking acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.Initial data from the phase reports that one of the most critical genes for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003. In addition, no toxicity observed at HT-003 doses as high as 50 µM."The ability of HT-003 to potently inhibit TLR2 expression suggests that this drug will not only be effective for acne but may also help a broad range of patients suffering from disease driven by over active inflammatory responses to bacteria," says Dr. Jonathan Zippin, Associate Professor of Dermatology at Weill Cornell Medicine and Hoth Senior Scientific Advisor.Hoth's CEO Robb Knie says: "We will continue to monitor the data at lower doses and move onto the testing

For further details see:

Hoth Therapeutics confirms HT-003 potential to inhibit acne pathogenic gene expression